← Back to Search

Fibroscan for Liver Cirrhosis

N/A
Waitlist Available
Led By Lawrence Worobetz, MD
Research Sponsored by University of Saskatchewan
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
-Any outpatient undergoing routine pacemaker interrogation at pacemaker clinic
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 min
Awards & highlights

Study Summary

This study is designed to determine if the Fibroscan (Echosens, Paris), a non-invasive, ultrasound-based device used to estimate fibrosis in patients with chronic liver disease, interferes with implanted cardiac pacemaker and/or implantable cardioverter-defibrillators. Recruitment consists of a total of 200 outpatients undergoing routine pacemaker interrogation at a teaching-hospital pacemaker clinic.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 min
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 min for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Rate of Pacemaker/ICD malfunction
Type of Pacemaker/ICD malfunction

Trial Design

1Treatment groups
Experimental Treatment
Group I: FibroscanExperimental Treatment1 Intervention
Fibroscan under simultaneous cardiac monitoring
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Fibroscan
2016
N/A
~1100

Find a Location

Who is running the clinical trial?

University of SaskatchewanLead Sponsor
251 Previous Clinical Trials
154,210 Total Patients Enrolled
Lawrence Worobetz, MDPrincipal InvestigatorUniversity of Saskatchewan

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
The Use of Fibroscan to Assess Liver Fibrosis in Patients With Cardiac Pacemakers
2015. "The Use of Fibroscan to Assess Liver Fibrosis in Patients With Cardiac Pacemakers". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02415348.
All > Fibrosis
~20 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top